Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Blackhawk Growth Corp C.BLR.WT


Primary Symbol: C.BLR Alternate Symbol(s):  BLRZF

Blackhawk Growth Corp. is a Canada-based investment holding company. The Company invests in equity and debt instruments of companies to generate positive returns for shareholders. It focuses on investing in multiple companies across a variety of sectors across North America. The Company has focused its investments on the health, cannabis and cannabidiol (CBD) industries, in both Canada and the... see more

CSE:BLR - Post Discussion

Blackhawk Growth Corp > BLACKHAWK UPDATES SAC PHARMA RESULTS AND OPERATIONS
View:
Post by bveilleu on Nov 30, 2020 10:17am

BLACKHAWK UPDATES SAC PHARMA RESULTS AND OPERATIONS

Vancouver, British Columbia - TheNewswire - November 30, 2020 - Blackhawk Growth Corp. (CSE:BLR ) (CNSX:BLR.CN) ( Frankfurt:0JJ ) ( OTC:BLRZF) (the " Company "), is pleased to provide an update on the operations of Sac Pharma Partners USA (" SAC Pharma "), its wholly owned subsidiary .

Blackhawk acquired Sac Pharma on July 23, 2020 and since the date of acquisition has trailing unaudited revenue for the 4 month period since the acquisition C$357,000, with gross margin of approximately C$278,000. Sac Pharma reached a significant milestone in the past 3 months by reaching a steady operational state. Sac Pharma is now on schedule to continue harvesting and distributing product monthly. This allows Sac Pharma to provide its customers consistent product, further strengthening the power of its supply chain. Sac Pharma's customer foundation has paved the way for expansion of its production footprint, and it is currently engaged in expanding the total square footage of growing space under its control.

Sac Pharma is the exclusive producer of Scoopz branded premium flower. Scoops is an Indica-dominant hybrid cannabis strain, bred by crossing three powerhouse strains, Gelato, Cookies & Cream, and Tina. THC levels have been testing at around 27%. This is a high end lifestyle brand whose products have been featured in pop culture & recording artist productions. Its name is synonymous with quality and for maintaining some of the best genetics in the industry. With products carried at Cookies Melrose, Cookies San Francisco, Dr. Greenthumbs stores in Sacramento and Los Angeles, and many other retailers statewide, this coveted high end product is allocated to sales reps and stores based on volume, and is sold out every harvest.


Click Image To View Full Size


Click Image To View Full Size

Scoopz also won 1 st place in the High Times Cup as a collaborating contributor for best indica dominant hybrid.

SAC Pharma has formed an extensive supply chain that spans the entire State of California, contracting with retailers and distributors in key markets including Los Angeles, San Francisco and Sacramento.

Sac Pharma's signature products include the coveted Black Truffle, White Truffle strains, along with Bacio and Gelato.


Click Image To View Full Size

"The team has done a great job timing production so we can provide the market with consistent, great quality product all year long" says Corey Travis, President of Sac Pharma. "This is especially important as demand surges amidst the COVID-19 pandemic. It has taken many months to streamline our production facility, but with that behind us, armed with proprietary data and unparalleled genetics, we see the ability to thrive in this growing marketplace. We are currently gearing up for a 2021 that will see record product delivered to customers who have pre-ordered to get in queue. We look forward to scaling with this incredibly loyal and growing customer base" continued Mr. Travis.

The Company cautions that figures for revenue and margin generated by Sac Pharma have not been audited and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited.

For more information on Blackhawk, please visit our website at:

https://www.blackhawkgrowth.com/

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@ blackhawkgrowth.com

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities